DavidRosmarinMD
Dermatology • Indianapolis, INInstructor in Dermatology, Brigham and Women's Hospital
Dr. Rosmarin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 University Blvd
Ste 3240
Indianapolis, IN 46202Phone+1 317-948-8657Fax+1 317-944-7051
Education & Training
Boston University Medical CenterResidency, Dermatology, 2006 - 2009
New York Presbyterian Hospital (Cornell Campus)Internship, Internal Medicine, 2005 - 2006
New York University School of MedicineClass of 2005
Certifications & Licensure
IN State Medical License 2022 - 2025
MA State Medical License 2008 - 2023
NY State Medical License 2013 - 2016- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
- Topical Ruxolitinib for the Treatment of Vitiligo Start of enrollment: 2016 Jan 01
- Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa Start of enrollment: 2016 Jul 11
- Join now to see all
Publications & Presentations
PubMed
- 28 citationsUnderstanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient SurveyJoe Gorelick, David Shrom, Kiran Sikand, Lisa Renda, Russel Burge
Dermatology and Therapy. 2019-10-19 - 14 citationsPsoriasis in Patients with Metabolic Syndrome or Type 2 Diabetes Mellitus: Treatment Challenges.Sukhmani Pannu, David Rosmarin
American Journal of Clinical Dermatology. 2021-02-15 - 59 citationsUpadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.Jonathan I. Silverberg, Marjolein S. de Bruin-Weller, Thomas Bieber, Weily Soong, Kenji Kabashima
The Journal of Allergy and Clinical Immunology. 2021-08-14
Press Mentions
Adolescents with Vitiligo Achieve Higher Repigmentation Rates with Topical Ruxolitinib Than AdultsJuly 16th, 2024- Seeing Red with DupilumabMarch 1st, 2023
- Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of MedicineOctober 20th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
